Tafamidis for treatment of Transthyretin cardiac amyloidosis: a real world experience
Anno:
2024
Background: a regional network for cardiac amyloidosis (CA) was created in 2019 with the aim of enhancing disease awareness among physicians and favoring appropriate access to innovative diagnostic tools/therapies. The network includes all 14 Cardiology Departments and outpatient clinics from 5 Local Health Units. Therapies for variant (ATTR-v) and…